Neuralstem Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial

Neuralstem, a biotech company with a patent on producing neural stem cells, is seeking approval from the FDA to launch a Phase 1 safety clinical trial aimed at using stem cells to treat spinal cord injuries. The application was born in part out of lessons learned from the ongoing Neuralstem clinical trial involving transplanting stem cells into six ALS patients.

Click here to read more.

Share this: